Published on : Mar 19, 2015
AbbVie, the subsidiary of the former unified Abbott Laboratories and a company that focuses on research based pharmaceuticals, has announced that it has signed an exclusive global license agreement with C2N Diagnostics to develop and market a collection of anti-tau antibodies that will be used to treat a variety of neurological disorders such as Alzheimer ’s disease.
C2N Diagnostics is a privately held company that focuses on protein diagnostic and therapeutic discovery. The partnership is a step forward by AbbVie towards its commitment towards pursuing transformational disease modifying therapies for the Alzheimer’s, a condition that is a highly dreaded form of neurological conditions and accounts for at least 60 to 70 per cent of cases of dementia.
Tau proteins help in stabilizing the proteins that are responsible for the transport and structure in neuronal cells. When tau proteins become defective and are no longer capable of stabilizing microtubules (altered tau), the neuronal cells, properly, their accumulation in an abnormal quantity and form is a leading indicator of numerous neurodegenerative diseases such as Progressive Supranuclear Palsy, Corticobasal Degeneration, and most importantly the Alzheimer's Disease. In these diseases, the development of tau pathology strongly associates with the clinical progression of the disease.
Thus, there is a need for devising new approaches and therapies that would address Alzheimer's disease in an effective manner. Jim Sullivan, Ph.D., the vice president of AbbVie said that the anti-tau portfolio of C2N is one of the most promising approaches towards delaying the progression of the devastating neurological disorder. A combination of C2N’s world class expertise in Alzheimer's with AbbVie's capabilities in neuroscience will help in developing anti-tau antibodies and their rapid advancement into patients.
The financial terms of the collaboration are not yet disclosed.